Table of Contents
- What is BEFIRADOL (18F)?
- Purpose of the Study
- How BEFIRADOL (18F) Works
- Medical Condition: Cluster Headaches
- Study Design
- Eligibility Criteria
- Potential Benefits
What is BEFIRADOL (18F)?
BEFIRADOL (18F) is an investigational drug being studied for its potential in understanding cluster headaches, a type of nervous system disease. This substance is also known by several other names, including [18F]-NLX-112, [18F]-F13640, and BEFIRADOL F-18.[1] It’s important to note that BEFIRADOL (18F) is not a treatment for cluster headaches, but rather a tool used in research to help scientists better understand this painful condition.
Purpose of the Study
The main goal of this study is to explore the underlying mechanisms of cluster headaches using BEFIRADOL (18F) in combination with advanced imaging techniques. Researchers aim to compare how this substance interacts with the brain during active headache periods and pain-free periods.[1] This comparison could provide valuable insights into why and how cluster headaches occur.
How BEFIRADOL (18F) Works
BEFIRADOL (18F) is designed to interact with specific receptors in the brain called 5-HT1A receptors. These receptors are involved in various brain functions, including pain perception. By using this substance, researchers can visualize and measure the activity of these receptors during different stages of cluster headaches.[1] This information could help explain why some people experience these intense headaches and potentially lead to better treatments in the future.
Medical Condition: Cluster Headaches
Cluster headaches, also known as AVF (Algie Vasculaire de la Face) in French, are a type of nervous system disease. They are characterized by severe, recurring pain on one side of the head, often described as one of the most painful conditions a person can experience. These headaches typically occur in cycles or “clusters,” hence the name.[1]
Study Design
The study is designed as an experimental, prospective, single-center, open-label trial. Participants will undergo two PET-MRI scans:
- During a cluster headache period
- During a pain-free remission period
During the cluster headache period, researchers will attempt to capture data before, during, and after a headache attack. To relieve the patient’s pain during the scan, a medication called sumatriptan will be injected.[1]
Eligibility Criteria
The study has specific criteria for who can participate. Some key inclusion criteria are:
- Male patients
- Age between 20 and 45 years
- Experiencing episodic cluster headaches
- Headache attacks occurring between 11:00 AM and 9:00 PM
- No psychiatric or neurological history other than cluster headaches
There are also several exclusion criteria, such as substance dependence, participation in other medical studies, and certain medical conditions that could interfere with the imaging procedures.[1]
Potential Benefits
While this study does not offer direct treatment for cluster headaches, it has the potential to greatly advance our understanding of this condition. By comparing brain activity and receptor density during headache and headache-free periods, researchers hope to uncover new insights into the mechanisms behind cluster headaches. This knowledge could potentially lead to the development of more effective treatments in the future, bringing hope to those who suffer from this debilitating condition.[1]
